Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
EC Healthcare (2138.HK)
Mong Kok, HK
EC Healthcare, an investment holding firm, delivers an extensive range of medical and healthcare services throughout Hong Kong, Macau, and mainland China. Its operations are structured into three primary divisions: Medical, Aesthetic Medical and Beauty and Wellness, and an 'Others' category. The company's diverse service offerings include quasi-medical treatments, beauty and wellness programs, medical imaging, surgical procedures, aesthetic medicine, dentistry, hair restoration, vaccinations, chiropractic care, psychological support, and orthopedic services. Beyond direct patient care, EC Healthcare also provides administrative and management support, laboratory diagnostics, various marketing and performance marketing solutions, and even travel agency services. Furthermore, it retails beauty and skincare products, manages healthcare machinery, engages in property investment, offers multi-channel networking, and extends its expertise to veterinary services. Its product and service portfolio is primarily marketed under proprietary brands such as PRODERMA LAB, Swissline, Suissebeaute, and re:HEALTH. Established in 2005 and headquartered in Mong Kok, Hong Kong, the company was formerly known as Union Medical Healthcare Limited before rebranding to EC Healthcare in April 2021.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.20% | +1.23% | -9.89% | -28.07% | -32.79% | -30.51% | -32.79% | -90.17% | -97.01% | -82.92% | -86.24% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-03 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Household & Personal Products: +3.3%-8.9% Q1'26: -12.0% (vs Q1'24)
-
EPS growth Household & Personal Products: +8.8%-142.9% Q1'26: -1,427.8% (vs Q1'24)
-
FCF margin FCF growth · Household & Personal Products: +44.8%+12.5% Q1'26: +15.8% (vs Q1'24)
-
EBIT margin Household & Personal Products: +9.9%+0.9% Q1'26: -0.2% (vs Q1'24)
-
ROIC Household & Personal Products: +8.2%+1.8% Q1'26: -0.6% (vs Q1'24)
-
Share dilution Household & Personal Products: +0.2%+0.0% Q1'26: 0.0% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Household & Personal Products: -0.51×2.30× Q1'26: -97.65× (vs Q1'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
704.94M
est: 673.50M (+4.7%)
|
964.93M
est: 886.00M (+8.9%)
|
1.31B
est: 1.31B (0.0%)
|
1.84B
est: 1.75B (+5.2%)
|
1.95B
est: 1.99B (-2.0%)
|
2.08B
est: 1.95B (+6.9%)
|
2.92B
est: 2.78B (+4.9%)
|
3.88B
est: 3.83B (+1.3%)
|
4.21B
est: 4.33B (-2.8%)
|
4.14B
est: 4.44B (-6.8%)
|
4.75B
4.75B – 4.75B
+6.9% YoY
|
5.02B
5.02B – 5.02B
+5.7% YoY
|
| EBITDA |
209.46M
est: 147.11M (+42.4%)
|
274.12M
est: 193.52M (+41.6%)
|
368.34M
est: 391.51M (-5.9%)
|
514.57M
est: 381.21M (+35.0%)
|
624.37M
est: 586.90M (+6.4%)
|
599.41M
est: 310.06M (+93.3%)
|
802.68M
est: 409.09M (+96.2%)
|
786.56M
est: 479.46M (+64.0%)
|
743.26M
est: 594.34M (+25.1%)
|
619.28M
est: 843.28M (-26.6%)
|
901.40M
901.40M – 901.40M
+6.9% YoY
|
952.87M
952.87M – 952.87M
+5.7% YoY
|
| EBIT |
184.82M
est: 46.16M (+300.4%)
|
244.95M
est: 60.73M (+303.3%)
|
330.72M
est: 354.42M (-6.7%)
|
452.82M
est: 119.63M (+278.5%)
|
378.59M
est: 531.30M (-28.7%)
|
289.54M
est: 367.99M (-21.3%)
|
370.32M
est: 485.53M (-23.7%)
|
199.83M
est: 569.05M (-64.9%)
|
117.71M
est: 705.39M (-83.3%)
|
-11.70M
est: 189.01M (-106.2%)
|
202.03M
202.03M – 202.03M
+6.9% YoY
|
213.57M
213.57M – 213.57M
+5.7% YoY
|
| Net Income |
148.66M
est: 248.89M (-40.3%)
|
200.70M
est: 256.93M (-21.9%)
|
279.22M
est: 290.36M (-3.8%)
|
361.11M
est: 438.53M (-17.7%)
|
286.58M
est: 435.27M (-34.2%)
|
192.87M
est: 278.64M (-30.8%)
|
197.50M
est: 367.64M (-46.3%)
|
69.65M
est: 69.65M (+0.0%)
|
-18.95M
est: -18.95M (+0.0%)
|
-167.19M
est: 11.85M (-1,510.6%)
|
11.85M
11.85M – 11.85M
+0.0% YoY
|
23.70M
23.70M – 23.70M
+100.0% YoY
|
| SGA |
123.18M
est: 70.39M (+75.0%)
|
187.00M
est: 92.60M (+102.0%)
|
300.52M
est: 741.63M (-59.5%)
|
154.54M
est: 182.40M (-15.3%)
|
124.44M
est: 1.11B (-88.8%)
|
226.40M
est: 976.45M (-76.8%)
|
302.02M
est: 1.29B (-76.6%)
|
405.36M
est: 1.51B (-73.2%)
|
426.37M
est: 1.87B (-77.2%)
|
432.37M
est: 367.63M (+17.6%)
|
392.97M
392.97M – 392.97M
+6.9% YoY
|
415.41M
415.41M – 415.41M
+5.7% YoY
|
| EPS |
0.20
est: 0.21 (-4.8%)
|
0.21
est: 0.22 (-3.1%)
|
0.28
est: 0.23 (+20.9%)
|
0.37
est: 0.37 (+0.0%)
|
0.29
est: 0.34 (-14.7%)
|
0.19
est: 0.16 (+15.9%)
|
0.17
est: 0.27 (-37.0%)
|
0.06
est: 0.18 (-66.8%)
|
-0.02
est: 0.04 (-137.2%)
|
-0.14
est: 0.01 (-1,500.0%)
|
0.01
0.01 – 0.01
+0.0% YoY
|
0.02
0.02 – 0.02
+100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-28 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-27 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-26 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-22 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-21 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-20 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-19 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-18 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-15 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-14 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-13 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-12 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 9.5K | 0.22% |
| 2 | Avantis Responsible International Equity ETF AVSD | 0.00% | 144.33 | 0.23% |
| 3 | Avantis International Small Cap Equity ETF AVDS | 0.00% | 48.08 | 0.30% |
| 4 | Avantis International Equity ETF AVDE | 0.00% | 2.4K | 0.23% |
| 5 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 957.07 | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Lyn Wade Lu | Chief Executive Officer & Executive Director | 5M | male |
| Heung Wing Lee | Chief Financial Officer & Executive Director | 4M | male |
| Chi Fai Tang | Founder & Executive Chairman | 1M | male |
| Chun Pong Siu | Company Secretary | — | male |
| Julie Chow | Chief Proposition Officer of Healthcare | — | — |
| Kin Keung Chan | Chief Public Affairs Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2138.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
